AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series [Yahoo! Finance]
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
AIM ImmunoTech GAAP EPS of -$1.57 misses by $0.59 [Seeking Alpha]
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer [Yahoo! Finance]